Drug Pricing

Addressing the issue of skyrocketing drug prices, including excessive price increases on commonly used generic medications and significant increases charged by pharmacy benefit managers (PBMs), is one of ASHP’s highest and longstanding public policy priorities. ASHP has been proactively addressing and tackling challenges related to drug pricing on several fronts, including working with likeminded stakeholders and educating members of Congress about the unsustainable burdens faced by patients, our members, and the entire healthcare system.

Impact of Rising Drug Prices and Drug Shortages on Patients and Hospitals

ASHP, with the American Hospital Association and the Federation of American Hospitals, recently issued a report — Recent Trends in Hospital Drug Spending and Manufacturer Shortages — which shows that rising drug prices and shortages of critical medications are impacting patient care and straining hospital budgets and operations.

Legislative Advocacy

ASHP and Other Healthcare Organizations Send Joint Letter to the Senate in Support of PBM Legislation (PDF)

ASHP and Other Healthcare Organizations Send Joint Letter to the Senate Calling for the End of DIR Fees (PDF)

ASHP and Other Healthcare Organizations Send Joint Letter to the US House of Representatives Calling for the End of DIR Fees (PDF)

ASHP Sends Letter to US House of Representative Leadership Regarding Vote on Drug Pricing Legislation

ASHP Statement for the Record: Improving Safety and Transparency in America’s Food and Drugs

ASHP Statement for the Record: "Investing in the U.S Health System by Lowering Drug Prices, Reducing Out-Of-Pocket Costs, and Improving Medicare Benefits"

ASHP Statement for the Record: “Making Prescription Drugs More Affordable: Legislation to Negotiate a Better Deal for Americans”

ASHP Submits Comments on the “The Prescription Drug Pricing Reduction Act (PDPRA) of 2019”

ASHP Joins Stakeholders in Asking Congress to DIR Fee Reform in Drug Pricing Legislation

ASHP Submits Comments on the Lower Health Care Costs Act of 2019

ASHP Statement for the Record: Improving Drug Pricing Transparency and Lowering Prices for American Consumers

ASHP Statement for the Record: "Lowering Drug Prices: Deconstructing the Drug Supply Chain"

ASHP Statement for the Record: “Drug Pricing in America: A Prescription for Change, Part III”

ASHP Statement for the Record: “Priced Out of a Lifesaving Drug: Getting Answers on the Rising Cost of Insulin”

ASHP Submits Letter of Support for the CREATES Act of 2019 and Protecting Consumer Access to Generic Drugs Act of 2019

ASHP Statement for the Record: "Lowering the Cost of Prescription Drugs: Reducing Barriers to Market Competition"

ASHP Statement for the Record: “The Complex Web of Prescription Drug Prices, Part II: Untangling the Web and Paths Forward”

ASHP Statement for the Record: “Promoting Competition to Lower Medicare Drug Prices”

ASHP Statement for the Record: “Drug Pricing in America: A Prescription for Change, Part II”

ASHP Statement for the Record: "The Cost of Rising Prescription Drug Prices"

ASHP Joins Campaign for Sustainable Rx Pricing (CSRxP) in Supporting CREATES Act

ASHP Statement for the Record: "Drug Pricing in America: A Prescription for Change, Part I"

ASHP Submits Letter to Committee Leadership: Examining the Actions of Drug Companies in Raising Prescription Drug Prices"

ASHP Joins CSRxP Letter Encouraging Senate Committee of CREATES Act

ASHP Statement for the Record: The Cost of Prescription Drugs: How the Drug Delivery System Affects What Patients Pay, Part II

ASHP Statement for the Record: “Antitrust Concerns and the FDA Approval Process”

ASHP Statement for the Record: “The Cost of Prescription Drugs: How the Drug Delivery System Affects What Patients Pay”

ASHP Efforts to Address Drug Pricing

ASHP Issue Brief Direct and Indirect Remuneration Fees

ASHP Statement for the Record: House Hearing on Developments in the Prescription Drug Market

ASHP Statement for the Record: Senate Special Committee on Aging Hearing on Generic Drug Prices

Campaign for Sustainable Rx Pricing (CSRxP) User Fee Comment Letter [PDF]

Campaign for Sustainable Rx Pricing (CSRxP) CREATES Act Endorsement Letter [PDF]

Regulatory Advocacy

ASHP Submits Comments to the FTC on PBM Practices [PDF] 

ASHP Submits Comments to CMS regarding the Most Favored Nation (MFN) Model

ASHP Issue Brief:  “Most Favored Nations” Drug Pricing Executive Order

ASHP and State Affiliates Joint Comments on Importation of Prescription Drugs

Joint Comments: Importation of Prescription Drugs Proposed Rule

ASHP Issue Brief: Safe Importation Action Plan

ASHP Issue Brief: Health Care Transparency Executive Order

ASHP Issue Brief: CMS Final Rule – “Modernizing Part D and Medicare Advantage to Lower Drug Prices and Reduce Out-of-Pocket Expenses”

ASHP Comments on Rebates Safe Harbor Proposed Rule

ASHP Comments on the Advanced Notice of Proposed Rulemaking:  International Pricing Index Model for Medicare Part B Drugs

ASHP Analysis of Trump Administration Drug Pricing and Payment Plan 2018

ASHP Submits Comments to the HHS Blueprint to Lower Drug Prices and Reduce Out-of-Pocket Costs

ASHP Analysis of the Administration's Drug Pricing Blueprint

ASHP Comments on CMS Part D Proposed Rule

State Advocacy

ASHP Issue Brief: States Should Oppose Wholesale Drug Importation

Issue Brief: State Drug Pricing